1[3]I-BFM-SG protocol and committee Progress report. BFM-Austria·Germany· Switzeri· and, ALL-BFM Pilot and ALL-BFM 2000,Preliminary report, 2003
2[4]Naito K, Takeshita A, Matsui H, et al. Multidrug resistance(MDR) -related protein 1 (MRP1) and lung resistance protein (LRP) are not the main drug resistance mechanisms of gemtuzumab ozogamicin (CMA-676) in AML. Hematol, J 2003, 3:1048
3[5]Matsui H, Takeshita A, Naito K, et al. Reduced effect of gemtuzumab ozogamicin (CMA-676) on Pglycoprotein and/or CD34 positive leukemia cells and its restoration by multidrug resistancemodifiers. Leukemia, 2002, 16:813
4[6]Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med, 2002, 346:645
5[7]IBMTR·ABMTR Summary slides2003, 10 (1)
6[8]Hoover RR, Mahon FX, Melo JV, et al. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.Blood, 2002, 100:1068
7[9]Guglielmi C, Arcese W, Dazzi F, et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: Prognostic relevance of the initial cell dose. Blood, 2002, 100:397
8[10]Ma J, Liu JW, Chen LY, et al. Clinical observations on arsenic trioxide (As2 O3 ) and all-trans retinoic acid (ATRA) in the treatment of acute promyelocytic leukemia (APL)[Abstract1991]. Blood, 1998, 92 (Suppl 1) :483A
9[12]Wang ZY, Chen Z. Differentiation and apoptosis induction therapy in acute promyelocyticleukemia [ review]. Lancet Oncol, 2000, 1:101
10[13]Wzhang ZY. Treatment of acute leukemia by inducing differentiation and apoptosis. Blood, 2003, 1
